Efficacy of risperidone on positive features of schizophrenia

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Dopaminergic hyperactivity mediated via D2 receptors is implicated in the etiology of positive symptoms of schizophrenia, but selective D2 antagonists provide imperfect therapy. This article describes a subanalysis of a trial of risperidone, a combined 5-HT(2A)/D2 antagonist, in 513 patients with DSM- III-R chronic schizophrenia. Risperidone at 2, 6, 10, and 16 mg/day was compared with placebo and haloperidol 20 mg/day. All doses of risperidone and the 20-mg dose of haloperidol were superior to placebo (mean change from baseline on the PANSS positive and general psychopathology subscales). The 6- mg dose of risperidone also produced significantly more improvement than haloperidol 20 mg. We conclude that risperidone is an effective drug for patients with positive features of schizophrenia.

Original languageEnglish (US)
Pages (from-to)18-21
Number of pages4
JournalJournal of Clinical Psychiatry
Volume55
Issue number5 SUPPL.
StatePublished - Jun 20 1994
Externally publishedYes

Fingerprint

Risperidone
Schizophrenia
Haloperidol
Placebos
Psychopathology
Diagnostic and Statistical Manual of Mental Disorders
Serotonin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Efficacy of risperidone on positive features of schizophrenia. / McEvoy, Joseph Patrick.

In: Journal of Clinical Psychiatry, Vol. 55, No. 5 SUPPL., 20.06.1994, p. 18-21.

Research output: Contribution to journalArticle

@article{2720eb29952f49aea57159f324c9bb9b,
title = "Efficacy of risperidone on positive features of schizophrenia",
abstract = "Dopaminergic hyperactivity mediated via D2 receptors is implicated in the etiology of positive symptoms of schizophrenia, but selective D2 antagonists provide imperfect therapy. This article describes a subanalysis of a trial of risperidone, a combined 5-HT(2A)/D2 antagonist, in 513 patients with DSM- III-R chronic schizophrenia. Risperidone at 2, 6, 10, and 16 mg/day was compared with placebo and haloperidol 20 mg/day. All doses of risperidone and the 20-mg dose of haloperidol were superior to placebo (mean change from baseline on the PANSS positive and general psychopathology subscales). The 6- mg dose of risperidone also produced significantly more improvement than haloperidol 20 mg. We conclude that risperidone is an effective drug for patients with positive features of schizophrenia.",
author = "McEvoy, {Joseph Patrick}",
year = "1994",
month = "6",
day = "20",
language = "English (US)",
volume = "55",
pages = "18--21",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Efficacy of risperidone on positive features of schizophrenia

AU - McEvoy, Joseph Patrick

PY - 1994/6/20

Y1 - 1994/6/20

N2 - Dopaminergic hyperactivity mediated via D2 receptors is implicated in the etiology of positive symptoms of schizophrenia, but selective D2 antagonists provide imperfect therapy. This article describes a subanalysis of a trial of risperidone, a combined 5-HT(2A)/D2 antagonist, in 513 patients with DSM- III-R chronic schizophrenia. Risperidone at 2, 6, 10, and 16 mg/day was compared with placebo and haloperidol 20 mg/day. All doses of risperidone and the 20-mg dose of haloperidol were superior to placebo (mean change from baseline on the PANSS positive and general psychopathology subscales). The 6- mg dose of risperidone also produced significantly more improvement than haloperidol 20 mg. We conclude that risperidone is an effective drug for patients with positive features of schizophrenia.

AB - Dopaminergic hyperactivity mediated via D2 receptors is implicated in the etiology of positive symptoms of schizophrenia, but selective D2 antagonists provide imperfect therapy. This article describes a subanalysis of a trial of risperidone, a combined 5-HT(2A)/D2 antagonist, in 513 patients with DSM- III-R chronic schizophrenia. Risperidone at 2, 6, 10, and 16 mg/day was compared with placebo and haloperidol 20 mg/day. All doses of risperidone and the 20-mg dose of haloperidol were superior to placebo (mean change from baseline on the PANSS positive and general psychopathology subscales). The 6- mg dose of risperidone also produced significantly more improvement than haloperidol 20 mg. We conclude that risperidone is an effective drug for patients with positive features of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=0028243821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028243821&partnerID=8YFLogxK

M3 - Article

C2 - 7520904

AN - SCOPUS:0028243821

VL - 55

SP - 18

EP - 21

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5 SUPPL.

ER -